FOR IMMEDIATE RELEASE
December 23rd 2015, MONTREAL, QUEBEC – Relevium Technologies Inc. (TSX.V – “RLV”) (Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has successfully completed its 2015 AGM and has passed all of its corporate resolutions including changing its name to Relevium Technologies Inc. (“Relevium”), which now trades under the symbol “RLV” on the TSX Venture Exchange. The Company’s new corporate website and corporate information can be viewed at www.releviumcorp.com
Relevium Technologies Inc. holds the intellectual assets that the Company acquired on August 7, 2015 through the Qualifying Transaction between Ovid Capital and Bioflex Medical Magnetics in a wholly-owned subsidiary. This wholly-owned subsidiary will continue to operate independently and will launch a newly designed product line using its patented technology for application on direct-to-consumer devices for decreasing pain, improving recovery time and enhancing performance.
Leena Lakdawala, CEO of Relevium Technologies Inc. stated: “The change to Relevium Technologies reflects the Company’s shift in its corporate strategy to focus on growth through the acquisition of businesses, products and/or technologies all within the scope of the expanding health and wellness sector targeting three main verticals: Pain Relief, Injury Recovery and Active Performance”.
André Godin, Chairman of the Board of Relevium Technologies Inc. stated: “Today’s informed consumers are choosing active health and well-being strategies to improve their quality of life. People stay active longer, eat healthier and try to avoid dependency on medication. We at Relevium plan to create value through the acquisition of innovative technologies that help people stay active longer, decrease recovery time from injuries and improve overall fitness performance”.
In 2016, Management will remain actively engaged in the identification of potential acquisition targets as well as in the design and development of new wearable devices for application in all three of its verticals. In order to facilitate these initiatives, the board of directors will be appointing an Advisory Board to assist in management in delivering on its objectives.
The Company is also pleased to announce the addition of Dr. Ted Zablotsky, M.D. to the Board of Directors. Dr. Zablotsky is co-founder of BIOflex Medical Magnetics, Inc. and is a co-inventor of the US Patent currently owned by Bioflex Technologies Inc. Dr. Zablotsky has pioneered research and documentation of the effects of bio-magnetism on the body since 1985. A noted author and speaker, Dr. Zablotsky has been a driving force behind the clinical development, research and regulatory registrations that established the credibility of magnetic therapy.
About Relevium Technologies Inc.
Relevium Technologies Inc. is a publicly traded corporation focused on the acquisition of innovative products, technologies and/or businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance. The company holds patented intellectual property that use magnetic fields for use on direct-to-consumer wearables. The company plans to launch a new product line during fiscal 2016 initially through Direct-to-Consumer retail via e-commerce.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
CEO and Director
Wishing everyone a Healthy, Happy & Prosperous New Year!
For additional information, please contact:
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the business and operations of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of the Company to execute and achieve its business objectives. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.